anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A novel modified peptide AT-01 has been synthesized from the microbiomic secretory protein MPT63 of  Mycobacterium tuberculosis . This peptide (about 30 amino acids) contains a portion of the immunogenic region of MPT63 (131 amino acids). It has been found to stabilize SMAR1 (Scaffold Matrix Attachment Region Binding Protein 1), a tumor suppressor protein which is well characterized as anti-cancer. In subsequent reasearch, AT-01 was modified further to generate 6 new, independent peptides. Both ITC and docking studies supported the interaction between the various peptides and full-length/ Protein Binding Domain of SMAR1. Among the peptides AT-01C and AT-01D were found to be more effective than the other peptides. Hence, we have used AT-01C and AT-01D for the further experiments. AT-01D also attenuated cell migration of MDA-MB231 cells which supports the anti-metastatic activity. Inhibition of the cell growth from the Colony Formation Assays too supported its anticancer activity. It does not cause toxicity to the cells at high doses which demonstrates great potential value as a safe and effective cancer therapy.
PURPOSE: To obtain a base dryable in a short time after applied to the both sift and hard tissues in the oral cavity, free from a sense of incompatibility of the film formed after applied to the oral cavity, and subject to stay in the oral cavity for a long time. CONSTITUTION: This long-term sustainable base for oral cavity is obtained by formulating a lower alcohol solution of an acrylic polymer with a fatty acid alcohol ester. The acrylic polymer accounts for 10-30wt.% of the final base, being e.g. an ethyl acrylate-methyl methacrylate-ethyl methacrylate trimethylammonium chloride copolymer. The fatty acid alcohol ester is e.g. triethyl citrate, accounting for 5-30wt.% of the final base. The lower alcohol (e.g. ethanol) accounts for 20-70wt.% of the final base. It is preferable that the weight ratio of the acrylic polymer to the fatty acid alcohol ester be (2:1) to (3:2). This base is a viscous liquid, forming a uniform film in a short time when applied to the oral cavity; the film is firmly adherable esp. to the dentin and retains its high adhesive force even in water or saliva.
BACKGROUND: Acute gastroenteritis is a major cause of morbidity and mortality in children. The aim of this study was to explore assessment and management of children aged between 6 and 48 months presenting to the emergency department (ED) with acute gastroenteritis.
METHODS: This retrospective cohort study included 340 children aged 6-48 months. Data were collected by medical record audit for children presenting between 1 January and 31 December 2019.
RESULTS: General assessments were appropriate, specific dehydration assessment, blood pressure measurement and fluid balance chart documentation could be improved. Management of children with severe or no/mild dehydration was largely compliant with current recommendations: there was variability in management of children with moderate dehydration. There were no significant differences between Australian Aboriginal and non-Aboriginal children in terms of dehydration severity and pathology abnormalities, however there were differences in management strategies.
CONCLUSIONS: ED management of children with gastroenteritis was largely consistent with, or superior to, evidence-based recommendations. There was variability in the management of children with moderate dehydration and Australian Aboriginal children but it is unclear whether this is suboptimal or patient specific care. This study has highlighted areas for further research in this unique context.
A resolution method for axis chiral enantiomers of Lesinurad (2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid). In said method, inexpensive and readily available quinoline natural products and derivatives thereof such as quinine, cinchonine, quinidine or cinchonidine are used as resolving agents to react with a Lesinurad racemate in an organic solvent to form a salt, and acidification is carried out to dissociate the salt so as to obtain an optically pure (R)-or (S)-2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid. This method is convenient to operate. The Lesinurad axis chiral enantiomer in the R configuration can achieve a chiral purity ee of 100% and a total yield of 90% or more. The Lesinurad axis chiral enantiomer in the S configuration can achieve a chiral purity ee of 99.9% and a total yield of 80% or more. Furthermore, the chiral resolving agents used are cheap, easy to obtain, and can be easily recovered and reused, reducing the separation cost and facilitating industrial production.
OBJECTIVE: Holmes tremor (HT) is a complex syndrome characterized by resting, postural, and kinetic tremors. HT significantly impacts patients' quality of life (QOL) and daily activities. Conventional pharmacological treatments for HT often yield inconsistent results. Emerging surgical treatments such as deep brain stimulation and various thalamotomy techniques show promise but come with challenges, including adverse events (AEs) and potential tremor recurrence. This study aimed to evaluate the clinical outcomes of unilateral MRI-guided laser interstitial thermal therapy (MRIgLITT) thalamotomy in patients with medically intractable HT, focusing on tremor reduction, QOL, and AE incidence, and provide a comprehensive review of the literature on thalamotomy techniques for HT.
METHODS: Five patients with medically intractable HT underwent unilateral MRIgLITT thalamotomy between June 2020 and January 2023. Tremor severity was assessed using the Fahn-Tolosa-Marin Tremor Rating Scale (TRS) at baseline and at 3 and 12 months postoperatively. QOL was measured using the Quality of Life in Essential Tremor (QUEST) questionnaire and 39-item Parkinson's Disease Questionnaire (PDQ-39). Subjective patient-rated improvement was evaluated using the Patient Global Impression of Clinical Status (PGI-C) scale at 12 months. Cognitive performance was assessed using the Mini-Mental State Examination (MMSE) before the procedure and at 12 months postoperatively. AEs were monitored throughout the follow-up period.
RESULTS: The mean patient age was 50.2 ± 22.37 years, with a mean tremor duration of 5.8 ± 4.55 years. Significant tremor reduction was observed in the treated hand, with mean TRS scores decreasing from 19.00 ± 4.36 at baseline to 11.20 ± 4.44 (p = 0.043) at 3 months and 13.40 ± 5.94 (p = 0.042) at 12 months, indicating a relative reduction of 41.05% and 29.47%, respectively. A significant effect was observed on the QUEST scale at 3 months (p = 0.043), but this effect was no longer present at 12 months. No significant effect was found on the PDQ-39 QOL scale. The PGI-C scale showed a high mean subjective improvement of 88.60% ± 8.36% at 12 months. One patient experienced severe AEs, including dysarthria, hemiparesis, and swallowing difficulties, which required prolonged hospitalization and multidisciplinary rehabilitation, but regressed within 3 months. Cognitive performance, as measured by the MMSE, remained stable (p = 0.785).
CONCLUSIONS: Unilateral MRIgLITT thalamotomy showed promise as a treatment for medically intractable HT, providing significant tremor reduction with a favorable safety profile. However, the potential for tremor recurrence and minimal functional improvement in fine motor skills highlight the need for long-term follow-up and further research. Larger, multicenter studies are necessary to validate these findings.
Liraglutide is a GLP-1 agonists approved for the management of obesity. In the study, it will be Initiated at 0.6 mg subcutaneously daily for 1 week; increase by 0.6 mg/day in weekly intervals until a dose of 3 mg/day achieved. If patients do not tolerate an increased dose during dose escalation, dose escalation will be delayed for an additional week. The patient will continue at the maximal tolerated does up to 3mg per day. If the patient has not lost at least 4% of baseline body weight at 16 weeks from medication initiation, the medication will be discontinued.
Patients with bilateral cochlear implant for more than 11 months will take electrophysiological and psychoacoustic tests to measure ECAP, EABR, speech recognition, and MCL. The binaural interaction component will also be measured ; this will allow to perform binaural comparison.
The study will aim to enroll a diverse participant population generally representative of the US population with respect to race, ethnicity, and sex. The target age categories of 60-69 years and 70-79 years will be enriched to increase the number of cancer events that are observed during the study.
The invention relates to an orthopaedics externally used medicinale extract, the technical proposal is that bark of Chinese wisteria 1-5 parts, wild ampelopsis root 1-7 parts, siebold wildginger herb 0.2-1 part, clematis chinensis 0.5-5 parts, safflower 0.5-5 parts, long Chinese honey locust 0.2-1.2 parts, moghania philippinensis seed 0.2-1.5 parts, resinous carbon 0.2-1.5 parts, edible vinegar 1-1.5 parts, red granulated sugar 0.2-2 parts and alcohol 1-2.5 parts. The processing procedures of the invention are that (a) the carefully chosen clean bark of Chinese wisteria, wild ampelopsis root, siebold wildginger herb, clematis chinensis, safflower, long Chinese honey locust and moghania philippinensis seed are abraded into the powder separately. The fineness degree of the powder is between 200-300 mesh sizes and the powders are acquired according to the proportion and are mixed evenly. (b) Resinous carbon and red granulated sugar are charged according to the proportion and are stirred evenly. (c) Edible alcohol and vinegar are charged according to the proportion and are stirred evenly. (d) The invention is weighed and stored separately with oiled hard papers.
The invention discloses a preparation method of hydrogel capable of loading various molecules and used for healing infected wounds. The invention prepares the poly (acrylamide-co-acrylic acid) hydrogel (PAM-AA) by simple one-pot method thermal initiation. Acrylamide (AM) and Acrylic Acid (AA) are used as raw materials, ammonium persulfate/tetramethylethylenediamine (APS/TEMED) is used as an initiating system, N' -Methylene Bisacrylamide (MBA) is used as a cross-linking agent, and PAM-AA is formed by initiating polymerization under the heating condition. The polymerization reaction conditions are optimized, and the hydrogel with the lowest monomer residual rate is obtained. The prepared hydrogel can load and release various molecules through hydrogen bonds and electrostatic interaction. The doxycycline-loaded hydrogel has good in-vitro and in-vivo antibacterial activity on gram-positive bacteria and gram-negative bacteria. In a rat full-thickness skin defect wound model infected by methicillin-resistant staphylococcus aureus, the doxycycline-loaded hydrogel shows a good treatment effect and can remarkably promote wound healing. The invention has simple process flow, low production cost and good biological safety, and is expected to play a role in the field of medical antibacterial dressings.
In Taiwan, the prevalence of urinary incontinence (UI) in postmenopausal women was 29.8%. Previous studies have indicated that menopause may be associated with developing UI. As there are many estrogen receptors in pelvic floor, the estrogen decline after menopausal transition may lead to pelvic floor muscle dysfunction, and the subsequent development of UI. Pelvic floor muscle training (PFMT) has been recommended by the International Continence Society as the first-line conservative treatment for women with UI. In addition to the prevalent incontinence associated with postmenopausal status, many women tend to have a more sedentary lifestyle after menopausal transition. Previous studies have shown that a sedentary lifestyle is related to UI in older women and indicated the importance of physical activity on preventing incontinence. Regular physical exercise including aerobic exercise and resistance training has been proved to improve bone mineral density, stress management and autonomic functions in postmenopausal women. However, the effect of different intensity of physical exercise adding to PFMT on pelvic floor muscle function in postmenopausal women with UI remains unknown. Therefore, the aim of this study is to investigate the effect of different intensity of exercise on pelvic floor muscle function and health-related quality of life in postmenopausal women with UI.

This is a randomized controlled trial (RCT). Postmenopausal women with UI and a sedentary lifestyle will be recruited. Eligible participants will be randomly allocated to the high-intensity group to receive high intensity general exercise plus PFMT program, the low-intensity group to receive low intensity general exercise plus PFMT, or the control group to receive only PFMT. The intervention will be provided twice weekly for eight weeks. The assessments will be conducted at baseline and after 8-week intervention. The primary outcome is pelvic floor muscle function measured by manometry and through digital palpation. The secondary outcomes are symptom severity measured using the International Consultation on Incontinence Questionnaire -Urinary Incontinence Short Form (ICIQ-UI SF), health-related quality of life measured using the International Consultation on Incontinence Questionnaire Lower Urinary Tract Symptoms Quality of Life Module (ICIQ-LUTSqol), and physical activity levels measured by the International Physical Activity Questionnaire (IPAQ). In addition, the participants will be asked to complete a 3-day bladder diary. Data analysis will be performed using Statistical Product and Service Solutions (SPSS) version 22.0. For continuous data, analysis of covariance tests will be used for within-group and between-group comparisons, respectively. For categorical data, McNemar's tests and chi-square tests will be used for within-group and between-group comparisons. The significant level is set at p-value \< 0.05.
The invention relates to a mitochondrion-targeted BODIPY compound and a preparation method and application of liposome-encapsulated nanoparticles thereof. The BODIPY compound contains a cationic group, and is easy to combine with a negatively charged mitochondrial membrane in a cell so as to target the mitochondrial organelle of the cell. The liposome is wrapped by liposome, and liposome nano-particles with uniform particle size are prepared in aqueous solution. The nano-particles have high stability and good biocompatibility in aqueous solution. After the nano particles are taken up by tumor cells, the liposome structure is destroyed, and the released BODIPY compound is targeted to cell mitochondria. In addition, under the condition of 665nm illumination, active oxygen generated by the BODIPY compound generates oxidative damage to active molecules in mitochondria, thereby killing tumor cells. The liposome nano-particle can be used for delivering various photosensitizer drugs to be applied to tumor photodynamic therapy.
Chronic pelvic pain (CPP) may affect up to a quarter of all women. Traditionally, CPP has been thought to be driven by visceral pain mechanisms such as Interstitial Cystitis/Painful Bladder Syndrome (IC/PBS), Irritable bowel syndrome (IBS) and endometriosis. It is also established that these visceral pain conditions overlap with vulvodynia, fibromyalgia, depression, and anxiety. More recently, underlying pelvic floor myofascial (PFMP) and dyssynergia have been identified as additional overlapping CPP conditions. Prior work suggests PFMP may be a viscero-somatic response, however, PFMP as a compensatory consequence of other regional musculoskeletal (MSK) conditions has also been proposed. Indeed, across their lifespan, women face higher risks than men for a plethora of MSK injuries and chronic MSK conditions, including an increased prevalence of sports-related injuries, joint hypermobility, fibromyalgia, osteoarthritic conditions (post-menopause), and osteoporosis/osteoporosis-associated fractures. These elevated risks are thought to be due to the unique anatomic (structural), biomechanical, and hormonal factors that can be attributed to the physiologic process of pregnancy and aging. The current application aims to address the significant knowledge gap regarding the limited understanding of the neuromuscular function of the PFM in CPP as well as the role of overlapping MSK conditions and MSK health that may be influencing PFM response. The short-term goal is to examine PFM biomechanics by identifying the most precise muscle measures in women with CPP of various overlapping diagnoses compared to asymptomatic controls, along with assessing overall MSK health/physical activity. The long-term goal is to determine MSK pelvic pain mechanisms that will inform clinically relevant classification, develop evidence-based non-pharmacologic (physical therapy/exercise) treatments for women with CPP, and advance research tools in the area of PFM function and CPP as it relates to overall MSK health. Our innovative strategy combines neuromuscular measures using novel devices and validated measures in evaluating CPP, MSK health, and physical activity. Our central hypothesis is that women with CPP will demonstrate quantifiable PFM abnormalities and clinical MSK characteristics that differ from asymptomatic controls. The results from this study will have a significant public health impact with contributions of rigorous objective and comprehensive PFM and MSK methods, which will be suitable for future NIH clinical research networks/trials, to evaluate and assess the MSK contribution and potential treatment outcomes in women with CPP.
The mechanism by which subarachnoid hemorrhage (SAH) leads to chronic neurologic deficits is unclear. One possibility is that blood activates microglia to drive inflammation that leads to synaptic loss and impaired brain function. Using the endovascular perforation model of SAH in rats, we investigated short-term effects on microglia together with long-term effects on EEG and neurologic function for up to 3 months. Within the first week, microglia were increased both at the site of injury and diffusely across the cortex (2.5-fold increase in SAH compared to controls, p = 0.012). Concomitantly, EEGs from SAH animals showed focal increases in slow wave activity and diffuse reduction in fast activity. When expressed as a fast-slow spectral ratio, there were significant interactions between group and time (p < 0.001) with less ipsilateral recovery over time. EEG changes were most pronounced during the first week and correlated with neurobehavioral impairment. In vitro, the blood product hemin was sufficient to increase microglia phagocytosis nearly six-fold (p = 0.032). Immunomodulatory treatment with fingolimod after SAH reduced microglia, improved neurological function, and increased survival. These findings, which parallel many of the EEG changes seen in patients, suggest that targeting neuroinflammation could reduce long-term neurologic dysfunction following SAH.
Subjects will undergo a standardized heavy water dosing protocol for 2 days (1 "loading day", 1 "maintenance day") and consume a standardized diet for 2 days. On the experimental test day, a gastroscopy with collection of duodenal mucosa tissue samples will be performed.
BACKGROUND: Co-designed educational materials could significantly improve the likelihood of patients and visitors (consumers) escalating care through hospital systems. The objective was to investigate patients' and visitors' knowledge and confidence in recognizing and reporting patient deterioration in hospitals before and after exposure to educational materials.
METHODS: A multimethod design involved a convenience sample of patients and visitors at a South Australian hospital. Knowledge and confidence of participants to report patient deterioration was assessed using a validated questionnaire. Baseline group was surveyed, and a second group was surveyed after exposure to a poster and on-hold message relating to consumer-initiated escalation-of-care. Nominal data were examined using chi-square analysis, and ordinal data using the Mann-Whitney U test. Open-ended questions were examined using thematic analysis.
RESULTS: A total of 407 participants completed the study, 203 undertook the baseline survey, and 204 the postintervention survey. Respondents exposed to the educational materials reported significantly higher recognition of responsibility to report concerns about patient deterioration compared to controls (86.3% vs. 73.1%; p = 0.007). Respondents exposed to the educational materials also had better ability to identify signs that a patient was becoming sicker compared to controls (77.5% vs. 71.3%, p = 0.012). Four overarching themes emerged from the questions: patient/visitor understanding of key messages, patient/visitor recognition of deterioration, patient/visitor response to deterioration and patient/visitor recommendations.
CONCLUSION: Following educational interventions, patients and visitors report improved awareness of their role in recognizing and responding to clinical deterioration. They advise additional active interventions and caution that the materials should accommodate language, cultural, and disability needs.
Non-toric Multifocal IOL (Rayner) - Model M-Flex 630F - CE marked since 2006 (in routine use). Surgery is performed under topical anaesthesia. Preoperatively, the horizontal meridian will be marked in the sitting position with a blue marking pen or insulin syringe at the limbus. The temporal self sealing incision, injection of viscoelastic substance, capsulorhexis, phacoemulsification, irrigation/aspiration of cortical material and injection of viscoelastic substance into the capsular bag are performed as standard procedure. Corneal limbal relaxing incisions (LRI) according to the Donnenefeld nomogram will be performed combined with standard non-toric multifocal IOL.
Data sources of use for this study are: Medicare Database, Optum Database, and MarketScan Research Database. All data from years 2013-2020 (available data may vary depending on the database) will be analyzed in the study.

This study follows a sequential cohort monitoring design. The monitoring analysis will include 1) retrospective analysis of available data (2013-2018) at the time of first analysis (April 2021) and 2) prospective analysis of new data (2019-2020) as they become available to the researchers. Within each database and by frailty status (frail vs non-frail), the investigators will emulate annual updating of data by creating a propensity score (PS)-matched cohort of new users every 1-year interval. Each sequential cohort will be followed for development of the outcomes of interest. At the end of each interval, time-to-event data from all sequential cohorts will be pooled for outcome analysis. The surveillance will be performed by frailty status (frail vs non-frail) at the time of drug initiation.